Hugo P.
- Country
- France
- Department
- Oncology
Research Overview
- Non-Inferiority Study of Pembrolizumab Maintenance Therapy at Standard vs. Reduced Dose in Metastatic Non-Squamous Lung Cancer
- A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)
- Phase 3 Randomized, Double-blind, Placebo-controlled Study of Apalutamide and GnRH Agonist in High-risk Localized or Locally Advanced Prostate Cancer with Primary Radiation Therapy
Data & Insights
Has run more than one trial at 243 of 539 partner sites.
Specializations
Thoracic Oncology
Clinical activity is centered on non-small cell lung cancer, including advanced, metastatic, resectable, and perioperative settings. The portfolio also extends to biomarker-defined lung cancer populations such as EGFR exon 20 insertion, KRAS G12C, and PD-L1-selected disease, with interest in combination immunotherapy, targeted therapy, and post-surgical treatment strategies.
- Non-small cell lung cancer
- Metastatic lung cancer
- EGFR-mutated disease
- KRAS G12C-positive disease
- Immunotherapy in thoracic malignancies
Research interests also include lung cancer after prior treatment, maintenance approaches, and perioperative management of resectable disease.
Prostate Cancer and Genitourinary Oncology
The investigator is involved in prostate cancer research across localized, high-risk, hormone-sensitive, and metastatic castration-resistant prostate cancer settings. The therapeutic focus includes androgen receptor-directed treatment, radiotherapy combinations, and treatment intensification for patients with adverse biological features.
- Localized prostate cancer
- Metastatic castration-resistant prostate cancer
- Hormone-naïve prostate cancer
- High-risk prostate cancer
- Renal cell carcinoma
Additional activity includes kidney cancer after surgery and molecularly selected prostate cancer with homologous recombination repair alterations.
Hematologic Malignancies
Clinical research spans acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma, and other onco-hematology conditions. The therapeutic landscape includes relapsed or refractory disease, mutation-defined leukemia, and treatment support around allogeneic hematopoietic stem cell transplantation.
- Acute myeloid leukemia
- Myelodysplastic syndrome
- Multiple myeloma
- FLT3-mutated leukemia
- Hematopoietic stem cell transplantation
Interest also extends to acute lymphoblastic leukemia and other advanced blood cancers requiring targeted and immune-based strategies.
Inflammatory and Immune-Mediated Diseases
The investigator is active in trials for chronic inflammatory disorders, especially hidradenitis suppurativa, atopic dermatitis, and atopic hand eczema. The portfolio also includes severe asthma, chronic spontaneous urticaria, and giant cell arteritis, reflecting a strong therapeutic interest in immune-mediated skin and airway disease.
- Hidradenitis suppurativa
- Atopic dermatitis
- Atopic hand eczema
- Severe asthma
- Chronic spontaneous urticaria
Research also includes systemic sclerosis-associated interstitial lung disease and other inflammatory conditions requiring biologic therapy.
Solid Tumors and Thromboembolic Disease
Broader oncology activity includes colorectal cancer, pancreatic adenocarcinoma, gastric cancer, breast cancer, and bladder cancer, alongside studies in renal cell carcinoma and mesothelioma. The investigator also participates in research on venous thromboembolism, pulmonary embolism, and stroke prevention in high-risk vascular settings.
- Colorectal cancer
- Pancreatic adenocarcinoma
- Gastric adenocarcinoma
- Venous thromboembolism
- Stroke prevention
Additional interests include advanced solid tumors, metastatic disease, and supportive strategies in cancer-associated clotting risk.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.